AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation ... R&D Mene Pangalos said the new device would help support the use ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Apple's slate of 2025 products look to be dominated by a large number of low-cost and entry-level devices. Here's what to expect. With advancements like Apple Intelligence and all-new in-house ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

No longer is the stylus only useful to creatives and scribes, either. The pen makes interacting with your device a more organic experience, whether you jot down notes, revel in remote photography ...

Just before TikTok’s temporary ban, Charli D’Amelio surprised fans with a confession about the 2020 ‘anxiety pen’ controversy.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Charli D'Amelio has reignited her 2020 ‘anxiety pen' controversy involving a device many believed to be a vape. At the time, fans and influencers claimed it was an anxiety pen, a narrative D'Amelio ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...